Posted by Michael Wonder on 07 Dec 2020
Scynexis announces FDA acceptance and priority review of new drug application for oral ibrexafungerp for the treatment of vaginal yeast infections
7 December 2020 - 6 month Priority Review granted for ibrexafungerp with PDUFA target action date set for 1 June 2021.
Scynexis today announced that the U.S. FDA has accepted for filing the Scynexis’ new drug application for ibrexafungerp for the treatment of vulvovaginal candidiasis, also known as vaginal yeast infections.
